Stockscreener 앱 받기
2.65
0.76%
0.02
Acumen Pharmaceuticals Inc 주식(ABOS)의 최신 뉴스
Earnings call transcript: Acumen Pharmaceuticals Q4 2025 reveals strategic advancements - Investing.com
Patterns Watch: What is the earnings history of Acumen Pharmaceuticals IncSell Signal & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
Cantor Fitzgerald reiterates Acumen Pharmaceuticals stock rating - Investing.com
Acumen Updates Alzheimer’s Pipeline, Extends Cash Runway Into 2027 - TipRanks
ACUMEN PHARMACEUTICALS ($ABOS) Releases Q4 2025 Earnings - Quiver Quantitative
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business Highlights - The Manila Times
Earnings Scheduled For March 26, 2026 - Benzinga
Acumen (NASDAQ: ABOS) deepens 2025 loss but extends cash runway toward key Alzheimer’s data - Stock Titan
Alzheimer’s drug readout due in late 2026 as Acumen targets 2027 filing - Stock Titan
Acumen Pharmaceuticals, Inc. (Acumen Pharmaceuticals) recently officially released its annual financial report for the year ended December 31, 2025, and simultaneously reviewed the key business developments of the company over the past year. - Bitget
Acumen Pharmaceuticals Inc expected to post a loss of 45 cents a shareEarnings Preview - TradingView
Acumen Pharmaceuticals (ABOS) Projected to Post Earnings on Monday - Defense World
ABOS (Acumen Pharmaceuticals) PB Ratio : 1.74 (As of Mar. 23, 2026) - GuruFocus
If You Invested $1,000 in Acumen Pharmaceuticals, Inc. (ABOS) - Stock Titan
Aug Rallies: What hedge funds are buying Acumen Pharmaceuticals IncWeekly Trend Report & Trade Opportunity Analysis - baoquankhu1.vn
Wall Street Zen Downgrades Acumen Pharmaceuticals (NASDAQ:ABOS) to Sell - MarketBeat
RA CAPITAL MANAGEMENT, L.P. Increases Stake in Acumen Pharmaceuticals Inc - GuruFocus
Dip Buying: How does Acumen Pharmaceuticals Inc perform in inflationary periods2026 Intraday Action & Stepwise Trade Signal Implementation - baoquankhu1.vn
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2025 Financial Results on March 26, 2026 - The Manila Times
Alzheimer's drug developer Acumen sets March 26 results webcast - Stock Titan
Acumen Pharmaceuticals Spotlights Sabirnetug Phase II Progress, JCR Brain-Delivery Partnership at Conference - MarketBeat
RA Capital entities boost Acumen (NASDAQ: ABOS) stake with 6.1M-share grant - Stock Titan
Acumen Pharmaceuticals at Stifel Forum: Strategic Insights on Alzheimer’s Drug - Investing.com Canada
ABOS: Phase II Alzheimer's trial for sabirnetug targets late 2026 data, with EBD clinical entry by 2027 - TradingView
Acumen Pharmaceuticals, Inc. unveils novel antibodies targeting amyloid beta oligomers at ADPD2026 - Traders Union
Acumen Pharmaceuticals (NASDAQ:ABOS) Stock Price Expected to Rise, BTIG Research Analyst Says - Defense World
Acumen Pharma Presents Brain Delivery Studies at Alzheimer’s and Parkinson’s Diseases Conference 2026 - Yahoo Finance
RA Capital boosts Acumen (ABOS) ownership to 29.5% after $20M PIPE buy - Stock Titan
Acumen Unveils Enhanced Brain Delivery Technology and Latest Alzheimer's Research Findings at International AD/PD Conference - citybiz
Private placement at Acumen to advance EBD program - BioWorld MedTech
Acumen Pharmaceuticals (NASDAQ:ABOS) Price Target Raised to $8.00 - MarketBeat
Acumen Pharmaceuticals Presents Studies on Enhanced Brain Delivery, Biomarker Research, and Novel Antibodies at Advances in Alzheimer's Treatment at International Conference on Alzheimer's and Parkinson's Diseases 2026 - Bitget
Mouse study boosts brain delivery of Acumen’s Alzheimer’s antibody - Stock Titan
Acumen Raises Capital to Advance Enhanced Brain Delivery - The Globe and Mail
Dow Update: Whats Acumen Pharmaceuticals Incs historical return2026 Short Interest & Entry and Exit Point Strategies - baoquankhu1.vn
Institution Moves: Is Acumen Pharmaceuticals Inc a strong candidate for buy and hold2026 Macro Moves & Verified Chart Pattern Trade Signals - baoquankhu1.vn
Acumen Pharmaceuticals Raises $35.75 Million to Advance Enhanced Brain Delivery Alzheimer’s Therapy with Strong Preclinical Results 1 - Minichart
Acumen secures funding to advance enhanced brain delivery program - MSN
Acumen Pharmaceuticals, Inc. announced that it has received $35.749992 million in funding from RA Capital Management, L.P., ADAR1 Capital Management, LLC, Sands Capital Alternatives, LLC and other investors - marketscreener.com
Acumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio - Bitget
Acumen Pharmaceuticals Raises $35.75 Million in Private Placement to Fund EBD Program - TradingView
Acumen Pharmaceuticals (NASDAQ: ABOS) secures $35.75M to advance EBD Alzheimer’s program - Stock Titan
Acumen Pharmaceuticals announces $35.75 million Private Placement to advance potential best-in-class molecules from amyloid beta oligomer-selective enhanced brain delivery portfolio - marketscreener.com
Acumen Pharmaceuticals Announces $35.75 Million Private Placement To Advance Potential Best-In-Class Molecules From Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio - TradingView
ABOS SEC FilingsAcumen Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
ABOS Forecast, Price Target & Analyst Ratings | ACUMEN PHARMACEUTICALS INC (NASDAQ:ABOS) - ChartMill
Team members drive company mission, Acumen Pharmaceuticals, Inc. asserts - Traders Union
Acumen Pharma chief legal officer sells $6813 in stock By Investing.com - Investing.com Canada
Acumen (NASDAQ: ABOS) legal chief sells 2,090 shares after option exercise - Stock Titan
Acumen Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum - Bitget
Alzheimer's therapeutics developer joins Stifel 2026 virtual CNS forum - Stock Titan
Stock Market Recap: What is the earnings history of Acumen Pharmaceuticals Inc2026 Closing Moves & Daily Oversold Bounce Ideas - baoquankhu1.vn
Highs Report: Is Acumen Pharmaceuticals Inc a turnaround story2025 Fundamental Recap & Expert Verified Movement Alerts - baoquankhu1.vn
Aug Spikes: What is the earnings history of Acumen Pharmaceuticals Inc2025 Price Action Summary & Real-Time Volume Analysis - baoquankhu1.vn
Acumen Pharmaceuticals (NASDAQ: ABOS) files Form 144 for insider sale - Stock Titan
Acumen Pharmaceuticals to Highlight New Alzheimer’s Research Progress at AD/PD™ 2026 - citybiz
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Receives $6.80 Consensus Price Target from Analysts - Defense World
Acumen Pharma chief legal officer Meisner sells $28k in shares - Investing.com Australia
Acumen (NASDAQ: ABOS) CLO exercises options and sells 9,406 shares - Stock Titan
Acumen Pharmaceuticals to Showcase Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026 - mx.advfn.com
Acumen Pharmaceuticals to showcase advances in Alzheimer's treatment at international conference on Alzheimer's and Parkinson's diseases 2026 - marketscreener.com
Acumen Pharmaceuticals to Showcase Advances in Alzheimer's Treatment at International Conference on Alzheimer's and Parkinson's Diseases 2026 - Bitget
0.99%
3.03%
자본화:
|
볼륨(24시간):